<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230403057808N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-04-19</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Intrathecal injection of fentanyl and sufentanil along with bupivacaine in painless labor</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of intrathecal injection of fentanyl and sufentanil along with bupivacaine in the onset, duration and quality of painless labor; A randomized double-blind clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69384</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Eligible pregnant mothers who have given informed consent to participate in the study will be assigned to one of the two groups of bupivacaine with fentanyl and bupivacaine with sufentanil by an Anesthetist technician who is not involved in the study, with a random sequence in blocks of four created by computer (WinPepi software11.65), with the sequence of randomization blocks in a ratio of 1:1.Allocation concealment will be used for implementing the random sequence of participants in the study. So before assigning the person, the assigned group will not be This will prevent participants and researchers from knowing about the subsequent allocation. In order to maintain the random sequence, the outer surface of the envelopes is numbered in the same order. In order to maintain the random sequence, the outer surface of the envelopes will be numbered in the same order. At the time of registration of eligible patients for the study, one of the envelopes will be opened and the patient will be a candidate for one of the two methods of analgesia, Blinding description: In order to double-blind the study, the anesthesiologist who prepares the study drug also performs the neuraxial block in order to take the necessary actions in case of side effects. Data collection will be done by the anesthesia assistant responsible for the project. In this study, the pregnant mother and the evaluator will be unaware of the type of drug used.</study_design>
      <phase>3</phase>
      <hc_freetext>Intrathecal injection of fentanyl and sufentanil in combination with bupivacaine in onset, duration and quality of painless labor.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1: In sterile conditions, a 25-size needle (B.Brown company)will be entered into the intraspinal space through lumbar vertebrae L3-L4 or L4-L5, and after ensuring the flow of cerebrospinal fluid, the injection will be performed. In the bupivacaine-fentanyl group, 2.5 milligrams of bupivacaine (manufactured by Aspen Company) will be injected with 25 micrograms of fentanyl (manufactured by Darupakhsh Company, Iran). The total volume of the solution is one milliliter. Intervention 2: Intervention group2 : In sterile conditions, a 25-size needle (B.Brown company)will be entered into the intraspinal space through lumbar vertebrae L3-L4 or L4-L5, and after ensuring the flow of cerebrospinal fluid, the injection will be performed. In the bupivacaine-sufentanil group, 2.5 milligrams of bupivacaine (manufactured by Aspen Company) will be injected along with 2.5 micrograms of sufentanil (manufactured by Aburihan Company, Iran). The total volume of the solution is one milliliter.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Not decided yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Samaneh Ghazanfar Tehran</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Research Center, Alzahra Hospital, Namjoo Street, Rasht, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144654839</zip>
        <telephone>+98 13 3332 9524</telephone>
        <email>Tehranisamaneh88rasht@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Samaneh Ghazanfar Tehran</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Research Center, Alzahra Hospital, Namjoo Street, Rasht, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144654839</zip>
        <telephone>+98 13 3332 9524</telephone>
        <email>Tehranisamaneh88rasht@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Primiparous or multiparous pregnant mothers with term pregnancy
Single fetus
American Society of Anesthesiologists' (ASA) classification I, II
In the advanced stage of labor with cervical dilation at least 5 centimeter in Primiparous and at least 4 centimeter in multiparous mothers
Age more than 18 years
Tending to have painless labor</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Refusal to participate in the study by pregnant mothers
Obesity
Endocrine disease
Drug abuse
Allergy to study drugs
Regional anesthesia contraindications such as coagulopathy, high intracranial pressure and infection of injection site .</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O75.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Complication of labor and delivery, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: In sterile conditions, a 25-size needle (B.Brown company)will be entered into the intraspinal space through lumbar vertebrae L3-L4 or L4-L5, and after ensuring the flow of cerebrospinal fluid, the injection will be performed. In the bupivacaine-fentanyl group, 2.5 milligrams of bupivacaine (manufactured by Aspen Company) will be injected with 25 micrograms of fentanyl (manufactured by Darupakhsh Company, Iran). The total volume of the solution is one milliliter.</i_keyword>
      <i_keyword>Intervention group2 : In sterile conditions, a 25-size needle (B.Brown company)will be entered into the intraspinal space through lumbar vertebrae L3-L4 or L4-L5, and after ensuring the flow of cerebrospinal fluid, the injection will be performed. In the bupivacaine-sufentanil group, 2.5 milligrams of bupivacaine (manufactured by Aspen Company) will be injected along with 2.5 micrograms of sufentanil (manufactured by Aburihan Company, Iran). The total volume of the solution is one milliliter.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Mean time of onset of sensory block. Timepoint: At zero, 5, 10, 15, 30, 45, 60, 90, 120 and 150 minutes after injection. Method of measurement: Pinprick response in both lower limbs.</prim_outcome>
      <prim_outcome>Mean time of duration of sensory block. Timepoint: At zero, 5, 10, 15, 30, 45, 60, 90, 120 and 150 minutes after injection. Method of measurement: Pinprick response in both lower limbs.</prim_outcome>
      <prim_outcome>The state of motor block. Timepoint: At zero, 5, 10, 15, 30, 45, 60, 90, 120 and 150 minutes after injection. Method of measurement: Bromage test:  zero (full flexion of knees and ankles), one (ability to move only knees), two (ability to move only legs), and three (inability to move knees and feet).</prim_outcome>
      <prim_outcome>Labor pain score. Timepoint: At zero, 5, 10, 15, 30, 45, 60, 90, 120 and 150 minutes after injection. Method of measurement: Based on visual analog scale as 1-10.</prim_outcome>
      <prim_outcome>Satisfaction status of pregnant mothers with the quality of analgesia. Timepoint: After transferring pregnant mothers to recovery and stabilization of vital signs. Method of measurement: Numerical Rating (NRS) based on percentage.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Drug complications: (Blood pressure drop more than 20% of baseline, itching, chills, nausea and vomiting, cases leading to cesarean section). Timepoint: The duration of the procedure. Method of measurement: Observance.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-03-01</approval_date>
        <contact_name>Ethics committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for research, Shahid Siadati Avenue, Namjoo Street,Rasht Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
